1. Home
  2. YMAT vs CALC Comparison

YMAT vs CALC Comparison

Compare YMAT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo J-Star Holding Co. Ltd. Ordinary Shares

YMAT

J-Star Holding Co. Ltd. Ordinary Shares

SELL

Current Price

$2.23

Market Cap

8.1M

ML Signal

SELL

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

SELL

Current Price

$1.68

Market Cap

7.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
YMAT
CALC
Founded
1970
2011
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1M
7.6M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
YMAT
CALC
Price
$2.23
$1.68
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $38.00
AVG Volume (30 Days)
★ 5.7M
70.6K
Earning Date
10-23-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.92
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.44
52 Week High
$4.49
$72.00

Technical Indicators

Market Signals
Indicator
YMAT
CALC
Relative Strength Index (RSI) 57.80 54.56
Support Level $0.44 $1.00
Resistance Level $2.37 $2.31
Average True Range (ATR) 0.72 0.16
MACD 0.06 0.13
Stochastic Oscillator 29.91 80.72

Price Performance

Historical Comparison
YMAT
CALC

About YMAT J-Star Holding Co. Ltd. Ordinary Shares

J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: